Frost & Sullivan

News Frost & Sullivan

  • Drug developers rawn to orphan drugs market

    The global orphan drugs market presents plenty of opportunities for new drug development – while there are only 172 approved orphan therapies, over 6,800 orphan diseases exist according to the United States National Institute of Health (NIH). Advancements in drug discovery capabilities coupled with more

  • Live cell imaging revolutionises disease diagnostics and drug discovery

    Tremendous advances in electronics, optics, fluorescent tools, and molecular biology have made live cell imaging technologies more accessible to life scientists looking to understand biological dynamics and visualize cellular events in organisms. The foray of omics technologies and nanotechnologies more

  • Information technology awakens the sleep disorder diagnostic industry

    A large pool of undiagnosed patients and the growing population of the elderly in both Europe and North America point to a massive end-user market for sleep disorder diagnostics devices. The market is steadily drawing investors due to the visible tilt in preference from drugs to home care sleep test more

All news on frost & sullivan

Websites Frost & Sullivan


The Company Products & Technologies PR and Publications Career About ESBATech People Intellectual Property Directions Contact Drug Discovery Drug Development Company News Scientific Publications Upcoming Events PR Contact Why ESBATech Positions To apply Webmail   ESBATech, an Alcon Biomedical Resear more

Environmental LIMS | Public Health LIMS | Water Quality LIMS | Clinical LIMS from ChemWare

   RECOGNITION ABOUT CHEMWARE CONTACT US PARTNERS AND AFFILIATIONS CAREERS GUARANTEES   PRINTER FRIENDLY    - Software Quality Leadership - 2009 Fast 50 Award | 2008 Excellence in Innovation Award Top PHL Survey Ranking | Application Security Certification | Technology Quality Award - ChemWare Named more


  The Company Products & Technologies PR and Publications Career     Company News HUENENBERG and ZURICH, Switzerland – September 14, 2009 Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG Company gains access to proprietary antibody fragment technology particularly suited to treat eye diseases more

All websites on frost & sullivan
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE